• Improve patient comprehension and ultimately retention, compliance and commitment
• Improve consistency and quality with regard to delivery, tracking, monitoring/oversight and archival of all relevant informed consent information in a highly secured database
• Provide trial staff with centralized, real time overview of the trial enrollment and consent process across all sites / countries
• Improve the quality, efficiency, transparency and accountability of interactions between patients and site staff
• Simplify patient education, consenting and re-consenting and associated review and approval processes
Therefore, Novartis plans to proactively implement digital technology such as eICF into clinical trial in Japan in order to make the informed consent process more patient-centric and operationally efficient.